About Us


The company owns therapeutic compounds for inflammatory diseases.

Our vision

KUSTE BIOPHARMA expands the use of these molecules to inflammatory urological diseases whose medical needs are currently unmet, such as Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC).
Preclinical data also supports other possible developments, for example on Inflammatory Bowel Disease (IBD).

KUSTE BIOPHARMA has closed a relevant financial round to launch Phase 2 clinical studies on BPS/IC and preclinical studies on other applications.

& Partnerships

Kuste Biopharma

129 rue Servient
69326 Lyon Cedex 3

5 rue de Castiglione
75001 Paris

+33 (0) 481 133 530

Retour en haut